Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions
Breast Cancer
Interventions
GENETIC

Polygenic Risk Score

A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

Unknown

CancerCare Manitoba, Winnipeg

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

CancerCare Manitoba

OTHER

lead

Mayo Clinic

OTHER